Medical therapy versus percutaneous coronary interventions for patients with stable and unstable coronary artery...

Area of Science:

• Cardiology
• Interventional Cardiology
• Clinical Trials

Background:

• Coronary artery disease (CAD) affects millions globally, necessitating effective treatment strategies.
• The optimal management for stable CAD, particularly in low-to-intermediate risk patients, remains a subject of clinical debate.
• The Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial provides critical data for this discussion.

Purpose of the Study:

• To evaluate the comparative effectiveness of routine invasive treatment (revascularization) versus optimal medical therapy in patients with stable coronary artery disease (CAD).
• To determine the impact of revascularization on clinical outcomes, including mortality and non-fatal myocardial infarction, in patients with stable CAD.
• To inform clinical decision-making regarding the role of revascularization in the management of stable CAD.

Main Methods:

• The study involved a randomized controlled trial design comparing an invasive strategy (angioplasty with stenting or bypass surgery) plus optimal medical therapy against optimal medical therapy alone.
• Participants were patients with stable CAD and evidence of myocardial ischemia, randomized to either strategy.
• Clinical events were tracked over a median follow-up period of 4.6 years.

Main Results:

• No significant difference in the primary composite endpoint of death, non-fatal myocardial infarction, or other major cardiovascular events was observed between the invasive strategy and the optimal medical therapy group.
• Subsequent analyses showed no significant differences in all-cause mortality, cardiovascular mortality, or non-fatal myocardial infarction between the two groups.
• Patients in both groups experienced improvements in symptoms and quality of life with optimal medical therapy.

Conclusions:

• For patients with stable CAD and no high-risk features, an invasive strategy of revascularization does not reduce the risk of death or major cardiovascular events compared to optimal medical therapy alone.
• Optimal medical therapy should be the cornerstone of management for patients with stable CAD.
• Revascularization decisions should be individualized based on symptom burden, patient preference, and anatomical considerations, rather than solely on the expectation of improved survival.